Global Gene Therapy
Market Report
2024
Gene Therapy Market Report 2024 (Global Edition)
The global Gene Therapy market size is USD 2.7 billion in 2024. The Gene Therapy market will show the strongest growth with a compound annual growth rate (CAGR) of 17.9% from 2024 to 2031. This growth can be attributed to increasing advancements in genetic engineering and biotechnology.
The base year for the calculation is 2023 and 2019 to 2023 will be historical period. The year 2024 will be estimated one while the forecasted data will be from year 2025 to 2031. When we deliver the report that time we updated report data till the purchase date.
PDF Access: Password protected PDF file, Excel File Access: Quantitative data, PPT Report Access: For the presentation purpose, Cloud Access: Secure Company Account Access.
| Share your contact details to receive free updated sample copy/pages of the recently published edition of Gene Therapy Market Report 2024.
Global Gene Therapy Market Report 2024 Market Size Split by Type (Gene Silencing, Cell Replacement, Gene Augmentation, Others), by Vector (Viral Vectors, Non-Viral Vectors), by Therapeutic Area (Neuro...
According to Cognitive Market Research, the global Gene Therapy market size will be USD 2.7 billion in 2024 and will expand at a compound annual growth rate (CAGR) of 17.9% from 2024 to 2031.
| Base Year | 2023 |
| Historical Data Time Period | 2019-2023 |
| Forecast Period | 2024-2031 |
| Global Gene Therapy Market Compound Annual Growth Rate (CAGR) for 2024 to 2031 | 22.62% |
| Market Split by Type |
|
| Market Split by Vector |
|
| Market Split by Therapeutic Area |
|
| Market Split by Delivery Method |
|
| List of Competitors |
|
| Regional Analysis |
|
Country Analysis |
|
Key Qualitative Information Covered |
|
Report scope is customizable as we have a huge database of Gene Therapy industry. We can deliver an exclusive report Edition/Consultation as per your data requirements. Request for your Free Sample Pages.
Gene Therapy Market is Segmented as below. Particular segment of your interest can be provided without any additional cost. Download the Sample Pages!
Gene Therapy Market Report Description
Introduction of the Gene Therapy Market
The Gene Therapy market represents a revolutionary advancement in medical science, offering potential cures for various genetic disorders by directly modifying the genes causing these diseases. This market is driven by cutting-edge research and technological advancements that enable precise targeting and alteration of genetic material, promising transformative treatments for conditions like hemophilia, cystic fibrosis, and certain cancers. The rise in genetic and chronic diseases, coupled with increasing investments from pharmaceutical companies and venture capitalists, fuels market growth. However, the high costs of development, production, and treatment, along with stringent regulatory hurdles and complex approval processes, pose significant challenges. Despite these barriers, ongoing clinical trials and the potential for groundbreaking therapeutic outcomes continue to drive optimism and investment in the gene therapy sector, positioning it as a pivotal frontier in the future of medicine.
Market Dynamics of Gene Therapy Market
Key Drivers for Gene Therapy Market
- Rising Prevalence of Genetic Disorders and Chronic Diseases - The growing incidence of genetic disorders and chronic diseases is a significant driver of the gene therapy market. Conditions such as cystic fibrosis, hemophilia, muscular dystrophy, and certain types of cancers have limited treatment options and often require long-term management. Gene therapy offers a promising solution by addressing the underlying genetic causes of these diseases, potentially providing lasting cures. As awareness of these therapies increases among patients and healthcare providers, and as the number of individuals affected by genetic disorders continues to rise, the demand for innovative and effective treatment options like gene therapy is expected to grow.
- The favorable regulatory environment and increasing approvals are anticipated to drive the Gene Therapy market's expansion in the years ahead.
Key Restraints for Gene Therapy Market
- The regulatory challenges and lengthy approval processes hindering the rapid commercialization of gene therapy products, limiting the Gene Therapy industry growth.
- The market also faces significant difficulties related to high costs.
We have various report editions of Gene Therapy Market, hence please contact our sales team and author directly to obtain/purchase a desired Edition eg, Global Edition, Regional Edition, Country Specific Report Edition, Company Profiles, Forecast Edition, etc. Request for your Free Sample PDF/Online Access.
Gene Therapy Market Insights Video
In December 2023, Voyager Therapeutics and Neurocrine Biosciences initiated a strategic collaboration to commercialize and develop Voyager's GBA1 program and other innovative gene therapies targeting neurological disorders, promising advancements in this critical field of medicine. (Source:https://ir.voyagertherapeutics.com/news-releases/news-release-details/neurocrine-biosciences-and-voyager-therapeutics-enter-strategic)
Top Companies Market Share in Gene Therapy Industry: (In no particular order of Rank)
- Novartis AG (Switzerland)
- Gilead Sciences
- Inc. (US)
- uniQure NV (Netherlands)
- Oxford Biomedica PLC (UK)
- Spark Therapeutics
- Inc. (US)
- SIBONO (China)
- Bluebird Bio
- Inc. (US)
- Shanghai Sunway Biotech Co.
- Ltd. (China)
- Biogen (US)
- Dendreon Pharmaceuticals LLC (US)
- Amgen Inc. (US)
- AnGes
- Inc. (Japan)
- Enzyvant Therapeutics GmbH (Switzerland)
- Epeius Biotechnologies Corp. (US)
- Astellas Pharma
- Inc. (Japan)
- American Gene Technologies (US)
- BioMarin (US)
- Confidential Data
- Access The Paid Version
- Data Hidden
If any Company(ies) of your interest has/have not been disclosed in the above list then please let us know the same so that we will check the data availability in our database and provide you the confirmation or include it in the final deliverables.
Regional Analysis of Gene Therapy Market
Which Region Dominates the Gene Therapy Market in 2024?
According to Cognitive Market Research, North America dominated the market in 2024 and accounted for around 40% of the global revenue due to its robust healthcare infrastructure, significant investments in research and development, supportive regulatory environment (such as FDA approvals), and strong presence of biotechnology and pharmaceutical companies focused on gene therapy innovation and commercialization.
Which Region is Expanding at the Fastest CAGR?
Asia-Pacific stands out as the fastest-growing region in the Gene Therapy market due to rising healthcare expenditure, increasing awareness of genetic disorders, and supportive regulatory reforms. Moreover, expanding biotechnology infrastructure and a growing number of clinical trials contribute to the region's rapid adoption and advancement in gene therapy technologies.
The current report Scope analyzes Gene Therapy Market on 5 major region Split (In case you wish to acquire a specific region edition (more granular data) or any country Edition data then please write us on info@cognitivemarketresearch.com
- North America (United States, Canada, Mexico)
- Europe (United Kingdom, France, Germany, Italy, Russia, Spain, Sweden, Denmark, Netherlands, Switzerland, Belgium)
- Asia-Pacific (China, Japan, Korea, India, Australia, Philippines, Singapore, Malaysia, Thailand, Indonesia, Rest of APAC)
- South America (Brazil, Argentina, Colombia, Peru, Chile, Rest of South America)
- Middle East and Africa (Saudi Arabia, Turkey, Nigeria, UAE, Egypt, South Africa, GCC Countries, Rest of MEA)
Gene Therapy Market Share (%) by Region (2019-2031)
The above graph is for illustrative purposes only.
To learn more about geographical trends request the free sample pages.
Get Free Sample
Gene Therapy Market Analysis
Global Gene Therapy Market Report 2024 Edition talks about crucial market insights with the help of segments and sub-segments analysis. In this section, we reveal an in-depth analysis of the key factors influencing Gene Therapy Industry growth. Gene Therapy market has been segmented with the help of its Type, Vector Therapeutic Area, and others. Gene Therapy market analysis helps to understand key industry segments, and their global, regional, and country-level insights. Furthermore, this analysis also provides information pertaining to segments that are going to be most lucrative in the near future and their expected growth rate and future market opportunities. The report also provides detailed insights into factors responsible for the positive or negative growth of each industry segment.
Type Segment Analysis of Gene Therapy Market
Based on present and future trends, the market size is estimated from 2019 to 2031. Moreover, study also provides quantitative and qualitative analysis of each type to understand the driving factors for the fastest growing type segment for Gene Therapy market.
Type of Gene Therapy analyzed in this report are as follows:
- Gene Silencing
- Cell Replacement
- Gene Augmentation
- Others
Gene Therapy Market Share (%) by Type in 2019-2031
The above Chart is for representative purposes and does not depict actual sale statistics. Access/Request the quantitative data to understand the trends and dominating segment of Gene Therapy Industry. Request a Free Sample PDF!
Vector Segment Analysis of Gene Therapy Market
This report forecasts revenue growth at the global, regional, and country levels and provides an analysis of the latest industry trends and opportunities for each application of Gene Therapy from 2019 to 2031. This will also help to analyze the demand for Gene Therapy across different end-use industries. Our research team will also help acquire additional data such as Value Chain, Patent analysis, Company Evaluation Quadrant (Matrix), and much more confidential analysis and data insights.
Some of the key Vector of Gene Therapy are:
- Viral Vectors
- Non-Viral Vectors
Gene Therapy Market Share (%) by Vector in 2019-2031
2019
2023
2031
The above Graph is for representation purposes only. This chart does not depict actual Market share.
To learn more about market share request the free sample pages.
Get Free Sample
Gene Therapy Therapeutic Area Segment Analysis
Gene Therapy Market Therapeutic Area Segment Analysis
According to cognitive market research, neurology is the dominant category due to its focus on treating severe and often incurable neurological disorders such as Parkinson's disease, Alzheimer's disease, and certain types of genetic epilepsy. These conditions represent significant unmet medical needs, driving intensive research and development efforts in gene therapy. The complexity of neurodegenerative diseases necessitates targeted approaches that can modify or replace faulty genes to halt or reverse disease progression. Moreover, advancements in delivery methods, such as viral vectors capable of crossing the blood-brain barrier, enhance the feasibility of gene therapy applications in treating neurological disorders .
- Neurology
- Oncology
- Hepatology
- Others
Gene Therapy Delivery Method Segment Analysis
- In Vivo
- Ex Vivo
Author's Detail
David FullerSenior Analyst at Cognitive Market Research
I am working as a Senior Analyst with Cognitive Market Research in the areas of Industry Survey and Market Research/Analytics. I collaborate with CXOs, VPs, and other senior executives to understand their data needs and provide solutions and business strategy building.
I am working as a Senior Analyst with Cognitive Market Research in the areas of Industry Survey and Market Research/Analytics. I collaborate with CXOs, VPs, and other senior executives to understand their data needs and provide solutions and business strategy building. I fulfill data requirements with thorough research and analytics. ME and My research team provide intelligence on industry stats, market structure, company profiles/Competition Analysis, Forecast Mapping, and Recently started providing the COVID-19 Impact Analysis.
Specialties: Industry research, Company analysis, Location Strategy, Tech Research, Change Management, Process Improvement, Peer Group Benchmarking, Startup Ecosystem, Crypto Research, COVID19 Impact Analysis, etc.
Author's Conclusion
Our study will explain complete manufacturing process along with major raw materials required to manufacture end-product. This report helps to make effective decisions determining product position and will assist you to understand opportunities and threats around the globe.
The Global Gene Therapy Market is witnessing significant growth in the near future.
In 2023, the Gene Silencing segment accounted for noticeable share of global Gene Therapy Market and is projected to experience significant growth in the near future.
The Viral Vectors segment is expected to expand at the significant CAGR retaining position throughout the forecast period.
Some of the key companies Novartis AG (Switzerland) , Inc. (US) and others are focusing on its strategy building model to strengthen its product portfolio and expand its business in the global market.
Frequently Asked Questions
Please note, we have not disclose, all the sources consulted/referred during a market study due to confidentiality and paid service concern. However, rest assured that upon purchasing the service or paid report version, we will release the comprehensive list of sources along with the complete report and we also provide the data support where you can intract with the team of analysts who worked on the report.
Latest News about Gene Therapy Market
Sources from Manufacturing & Construction Industry
-
https://www.epa.gov/regulatory-information-sector/construction-sector-naics-23
-
https://www.usace.army.mil/Missions/Civil-Works/Engineering-and-Construction/
-
https://www.abs.gov.au/statistics/industry/building-and-construction
-
https://business.gov.au/planning/industry-information/construction-industry
-
https://www.usitc.gov/research_and_analysis/tradeshifts/2021/footwear
Gene Therapy Market Report Table of Content
Disclaimer:
- This is just a redacted sample pages of the actual deliverable report and only for representative purposes
- Charts/Graphs/Numbers/data are only for Representative purposes and do not depict actual statistics.
- The table of Contents differs according to the user License selection. Current Displayed TOC is for the Corporate User License Report Edition. TOC Customization options: Add or Remove section/s Or chapter/s from the report.
- Specific Tables, Graphs, Sections, and Chapters can be ordered at a discounted price.
- If applicable; On Request Volume Data will also be provided (at an Additional Cost).
| Type | Gene Silencing, Cell Replacement, Gene Augmentation, Others |
| Vector | Viral Vectors, Non-Viral Vectors |
| Therapeutic Area | Neurology, Oncology, Hepatology, Others |
| Delivery Method | In Vivo, Ex Vivo |
| List of Competitors | Novartis AG (Switzerland), Gilead Sciences, Inc. (US), uniQure NV (Netherlands), Oxford Biomedica PLC (UK), Spark Therapeutics, Inc. (US), SIBONO (China), Bluebird Bio, Inc. (US), Shanghai Sunway Biotech Co., Ltd. (China), Biogen (US), Dendreon Pharmaceuticals LLC (US), Amgen Inc. (US), AnGes, Inc. (Japan), Enzyvant Therapeutics GmbH (Switzerland), Epeius Biotechnologies Corp. (US), Astellas Pharma, Inc. (Japan), American Gene Technologies (US), BioMarin (US) |
This chapter will help you gain GLOBAL Market Analysis of Gene Therapy. Further deep in this chapter, you will be able to review Global Gene Therapy Market Split by various segments and Geographical Split.
Chapter 1 Global Market Analysis
-
1.1 Global Gene Therapy Market Size, Trend Analysis 2019 - 2031
-
1.2 Global Gene Therapy Market Size By Regions 2019 - 2031
Global Market has been segmented on the basis 5 major regions such as North America, Europe, Asia-Pacific, Middle East & Africa, and Latin America.
-
1.2.1 Global Gene Therapy Revenue Market Size By Region
-
-
1.3 Global Gene Therapy Market Size By Type 2019 -2031
-
1.3.1 Gene Silencing Market Size
-
1.3.2 Cell Replacement Market Size
-
1.3.3 Gene Augmentation Market Size
-
1.3.4 Others Market Size
-
-
1.4 Global Gene Therapy Market Size By Vector 2019 -2031
-
1.4.1 Viral Vectors Market Size
-
1.4.2 Non-Viral Vectors Market Size
-
-
1.5 Global Gene Therapy Market Size By Therapeutic Area 2019 -2031
-
1.5.1 Neurology Market Size
-
1.5.2 Oncology Market Size
-
1.5.3 Hepatology Market Size
-
1.5.4 Others Market Size
-
-
1.6 Global Gene Therapy Market Size By Delivery Method for 2019 -2031
-
1.6.1 In Vivo Market Size
-
1.6.2 Ex Vivo Market Size
-
-
1.7 Global Level Competitor Analysis (Subject to Data Availability (Private Players))
-
1.8 Executive Summary Global Market (2019 vs 2024 vs 2031)
You can purchase only the Executive Summary of Global Market (2019 vs 2024 vs 2031)
-
1.8.1 Regional Market Revenue Summary 2019 vs 2024 vs 2031
-
1.8.2 Global Market Revenue Split By Type
-
1.8.3 Global Market Revenue Split By Vector
-
1.8.4 Global Market Revenue Split By Therapeutic Area
-
1.8.5 Global Market Revenue Split By Delivery Method
-
1.8.6 Global Market Dynamics, Trends, Drivers, Restraints, Opportunities
Global Market Dynamics, Trends, Drivers, Restraints, Opportunities, Only Pointers will be deliverable
-
Chapter 2 North America Market Analysis
-
2.1 North America Gene Therapy Market Size 2019 - 2031
-
2.1.1 North America Gene Therapy Market Size By Country 2019 - 2031
-
2.1.2 North America Gene Therapy Market Size by Type 2019 -2031
-
2.1.2.1 North America Gene Silencing Market Size
-
2.1.2.2 North America Cell Replacement Market Size
-
2.1.2.3 North America Gene Augmentation Market Size
-
2.1.2.4 North America Others Market Size
-
-
2.1.3 North America Gene Therapy Market Size by Vector 2019 -2031
-
2.1.3.1 North America Viral Vectors Market Size
-
2.1.3.2 North America Non-Viral Vectors Market Size
-
-
2.1.4 North America Gene Therapy Market Size by Therapeutic Area 2019 -2031
-
2.1.4.1 North America Neurology Market Size
-
2.1.4.2 North America Oncology Market Size
-
2.1.4.3 North America Hepatology Market Size
-
2.1.4.4 North America Others Market Size
-
-
2.1.5 North America Gene Therapy Market Size by Delivery Method 2019 -2031
-
2.1.5.1 North America In Vivo Market Size
-
2.1.5.2 North America Ex Vivo Market Size
-
-
Chapter 3 Europe Market Analysis
-
3.1 Europe Gene Therapy Market Size 2019 - 2031
-
3.1.1 Europe Gene Therapy Market Size By Country 2019 - 2031
-
3.1.2 Europe Gene Therapy Market Size by Type 2019 -2031
-
3.1.2.1 Europe Gene Silencing Market Size
-
3.1.2.2 Europe Cell Replacement Market Size
-
3.1.2.3 Europe Gene Augmentation Market Size
-
3.1.2.4 Europe Others Market Size
-
-
3.1.3 Europe Gene Therapy Market Size by Vector 2019 -2031
-
3.1.3.1 Europe Viral Vectors Market Size
-
3.1.3.2 Europe Non-Viral Vectors Market Size
-
-
3.1.4 Europe Gene Therapy Market Size by Therapeutic Area 2019 -2031
-
3.1.4.1 Europe Neurology Market Size
-
3.1.4.2 Europe Oncology Market Size
-
3.1.4.3 Europe Hepatology Market Size
-
3.1.4.4 Europe Others Market Size
-
-
3.1.5 Europe Gene Therapy Market Size by Delivery Method 2019 -2031
-
3.1.5.1 Europe In Vivo Market Size
-
3.1.5.2 Europe Ex Vivo Market Size
-
-
Chapter 4 Asia Pacific Market Analysis
-
4.1 Asia Pacific Gene Therapy Market Size 2019 - 2031
-
4.1.1 Asia Pacific Gene Therapy Market Size By Country 2019 - 2031
-
4.1.2 Asia Pacific Gene Therapy Market Size by Type 2019 -2031
-
4.1.2.1 Asia Pacific Gene Silencing Market Size
-
4.1.2.2 Asia Pacific Cell Replacement Market Size
-
4.1.2.3 Asia Pacific Gene Augmentation Market Size
-
4.1.2.4 Asia Pacific Others Market Size
-
-
4.1.3 Asia Pacific Gene Therapy Market Size by Vector 2019 -2031
-
4.1.3.1 Asia Pacific Viral Vectors Market Size
-
4.1.3.2 Asia Pacific Non-Viral Vectors Market Size
-
-
4.1.4 Asia Pacific Gene Therapy Market Size by Therapeutic Area 2019 -2031
-
4.1.4.1 Asia Pacific Neurology Market Size
-
4.1.4.2 Asia Pacific Oncology Market Size
-
4.1.4.3 Asia Pacific Hepatology Market Size
-
4.1.4.4 Asia Pacific Others Market Size
-
-
4.1.5 Asia Pacific Gene Therapy Market Size by Delivery Method 2019 -2031
-
4.1.5.1 Asia Pacific In Vivo Market Size
-
4.1.5.2 Asia Pacific Ex Vivo Market Size
-
-
Chapter 5 South America Market Analysis
-
5.1 South America Gene Therapy Market Size 2019 - 2031
-
5.1.1 South America Gene Therapy Market Size By Country 2019 - 2031
-
5.1.2 South America Gene Therapy Market Size by Type 2019 -2031
-
5.1.2.1 South America Gene Silencing Market Size
-
5.1.2.2 South America Cell Replacement Market Size
-
5.1.2.3 South America Gene Augmentation Market Size
-
5.1.2.4 South America Others Market Size
-
-
5.1.3 South America Gene Therapy Market Size by Vector 2019 -2031
-
5.1.3.1 South America Viral Vectors Market Size
-
5.1.3.2 South America Non-Viral Vectors Market Size
-
-
5.1.4 South America Gene Therapy Market Size by Therapeutic Area 2019 -2031
-
5.1.4.1 South America Neurology Market Size
-
5.1.4.2 South America Oncology Market Size
-
5.1.4.3 South America Hepatology Market Size
-
5.1.4.4 South America Others Market Size
-
-
5.1.5 South America Gene Therapy Market Size by Delivery Method 2019 -2031
-
5.1.5.1 South America In Vivo Market Size
-
5.1.5.2 South America Ex Vivo Market Size
-
-
Chapter 6 Middle East and Africa Market Analysis
-
6.1 Middle East and Africa Gene Therapy Market Size 2019 - 2031
-
6.1.1 Middle East and Africa Gene Therapy Market Size By Country 2019 - 2031
-
6.1.2 Middle East and Africa Gene Therapy Market Size by Type 2019 -2031
-
6.1.2.1 Middle East and Africa Gene Silencing Market Size
-
6.1.2.2 Middle East and Africa Cell Replacement Market Size
-
6.1.2.3 Middle East and Africa Gene Augmentation Market Size
-
6.1.2.4 Middle East and Africa Others Market Size
-
-
6.1.3 Middle East and Africa Gene Therapy Market Size by Vector 2019 -2031
-
6.1.3.1 middle_east_and_africa_title} Viral Vectors Market Size
-
6.1.3.2 middle_east_and_africa_title} Non-Viral Vectors Market Size
-
-
6.1.4 Middle East and Africa Gene Therapy Market Size by Therapeutic Area 2019 -2031
-
6.1.4.1 Middle East and Africa Neurology Market Size
-
6.1.4.2 Middle East and Africa Oncology Market Size
-
6.1.4.3 Middle East and Africa Hepatology Market Size
-
6.1.4.4 Middle East and Africa Others Market Size
-
-
6.1.5 Middle East and Africa Gene Therapy Market Size by Delivery Method 2019 -2031
-
6.1.5.1 Middle East and Africa In Vivo Market Size
-
6.1.5.2 Middle East and Africa Ex Vivo Market Size
-
-
Only Available with Corporate User License
Chapter 7 Top 10 Countries Analysis (Only Available with Corporate User License)
-
7.1 Country 1 Market Analysis
-
7.1.1 Country 1Gene Therapy Market Size by Type 2019 -2031
-
7.1.2 Country 1Gene Therapy Market Size by Vector 2019 -2031
-
7.1.3 Country 1Gene Therapy Market Size by Therapeutic Area 2019 -2031
-
7.1.4 Country 1Gene Therapy Market Size by Delivery Method 2019 -2031
-
-
7.2 Country 2 Market Analysis
-
7.2.1 Segmentation Analysis will be provided as shown for Country 1
-
-
7.3 Country 3 Market Analysis
-
7.3.1 Segmentation Analysis will be provided as shown for Country 1
-
-
7.4 Country 4 Market Analysis
-
7.4.1 Segmentation Analysis will be provided as shown for Country 1
-
-
7.5 Country 5 Market Analysis
-
7.5.1 Segmentation Analysis will be provided as shown for Country 1
-
-
7.6 Country 6 Market Analysis
-
7.6.1 Segmentation Analysis will be provided as shown for Country 1
-
-
7.7 Country 7 Market Analysis
-
7.7.1 Segmentation Analysis will be provided as shown for Country 1
-
-
7.8 Country 8 Market Analysis
-
7.8.1 Segmentation Analysis will be provided as shown for Country 1
-
-
7.9 Country 9 Market Analysis
-
7.9.1 Segmentation Analysis will be provided as shown for Country 1
-
-
7.10 Country 10 Market Analysis
-
7.10.1 Segmentation Analysis will be provided as shown for Country 1
-
Competitor's Market Share and Revenue (Subject to Data Availability for Private Players)
Chapter 8 Competitor Analysis (Subject to Data Availability (Private Players))
-
8.1 Top Competitors Analysis
-
8.1.1 Top Players Ranking 2022
-
8.1.2 Global Gene Therapy Market Revenue and Share by Manufacturers (2019-2023)
(Subject to Data Availability (Private Players))
-
8.1.3 Industry Mergers and Acquisition Analysis
-
8.1.4 New Product Launch Analysis
-
-
8.2 Company Profile (Data Subject to Availability)
-
8.2.1 Novartis AG (Switzerland)
Data Subject to Availability as we consider Top competitors and their market share will be delivered.
-
8.2.1.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
-
8.2.1.2 Business Overview
-
8.2.1.3 Financials (Subject to data availability)
-
8.2.1.4 Product Types Specification
-
8.2.1.5 Business Strategy
-
8.2.1.6 S.W.O.TAnalysis
-
-
8.2.2 Gilead Sciences
Data Subject to Availability as we consider Top competitors and their market share will be delivered.
-
8.2.2.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
-
8.2.2.2 Business Overview
-
8.2.2.3 Financials (Subject to data availability)
-
8.2.2.4 Product Types Specification
-
8.2.2.5 Business Strategy
-
8.2.2.6 S.W.O.TAnalysis
-
-
8.2.3 Inc. (US)
Data Subject to Availability as we consider Top competitors and their market share will be delivered.
-
8.2.3.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
-
8.2.3.2 Business Overview
-
8.2.3.3 Financials (Subject to data availability)
-
8.2.3.4 Product Types Specification
-
8.2.3.5 Business Strategy
-
8.2.3.6 S.W.O.TAnalysis
-
-
8.2.4 uniQure NV (Netherlands)
Data Subject to Availability as we consider Top competitors and their market share will be delivered.
-
8.2.4.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
-
8.2.4.2 Business Overview
-
8.2.4.3 Financials (Subject to data availability)
-
8.2.4.4 Product Types Specification
-
8.2.4.5 Business Strategy
-
8.2.4.6 S.W.O.TAnalysis
-
-
8.2.5 Oxford Biomedica PLC (UK)
Data Subject to Availability as we consider Top competitors and their market share will be delivered.
-
8.2.5.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
-
8.2.5.2 Business Overview
-
8.2.5.3 Financials (Subject to data availability)
-
8.2.5.4 Product Types Specification
-
8.2.5.5 Business Strategy
-
8.2.5.6 S.W.O.TAnalysis
-
-
8.2.6 Spark Therapeutics
Data Subject to Availability as we consider Top competitors and their market share will be delivered.
-
8.2.6.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
-
8.2.6.2 Business Overview
-
8.2.6.3 Financials (Subject to data availability)
-
8.2.6.4 Product Types Specification
-
8.2.6.5 Business Strategy
-
8.2.6.6 S.W.O.TAnalysis
-
-
8.2.7 Inc. (US)
Data Subject to Availability as we consider Top competitors and their market share will be delivered.
-
8.2.7.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
-
8.2.7.2 Business Overview
-
8.2.7.3 Financials (Subject to data availability)
-
8.2.7.4 Product Types Specification
-
8.2.7.5 Business Strategy
-
8.2.7.6 S.W.O.TAnalysis
-
-
8.2.8 SIBONO (China)
Data Subject to Availability as we consider Top competitors and their market share will be delivered.
-
8.2.8.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
-
8.2.8.2 Business Overview
-
8.2.8.3 Financials (Subject to data availability)
-
8.2.8.4 Product Types Specification
-
8.2.8.5 Business Strategy
-
8.2.8.6 S.W.O.TAnalysis
-
-
8.2.9 Bluebird Bio
Data Subject to Availability as we consider Top competitors and their market share will be delivered.
-
8.2.9.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
-
8.2.9.2 Business Overview
-
8.2.9.3 Financials (Subject to data availability)
-
8.2.9.4 Product Types Specification
-
8.2.9.5 Business Strategy
-
8.2.9.6 S.W.O.TAnalysis
-
-
8.2.10 Inc. (US)
Data Subject to Availability as we consider Top competitors and their market share will be delivered.
-
8.2.10.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
-
8.2.10.2 Business Overview
-
8.2.10.3 Financials (Subject to data availability)
-
8.2.10.4 Product Types Specification
-
8.2.10.5 Business Strategy
-
8.2.10.6 S.W.O.TAnalysis
-
-
8.2.11 Shanghai Sunway Biotech Co.
Data Subject to Availability as we consider Top competitors and their market share will be delivered.
-
8.2.11.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
-
8.2.11.2 Business Overview
-
8.2.11.3 Financials (Subject to data availability)
-
8.2.11.4 Product Types Specification
-
8.2.11.5 Business Strategy
-
8.2.11.6 S.W.O.TAnalysis
-
-
8.2.12 Ltd. (China)
Data Subject to Availability as we consider Top competitors and their market share will be delivered.
-
8.2.12.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
-
8.2.12.2 Business Overview
-
8.2.12.3 Financials (Subject to data availability)
-
8.2.12.4 Product Types Specification
-
8.2.12.5 Business Strategy
-
8.2.12.6 S.W.O.TAnalysis
-
-
8.2.13 Biogen (US)
Data Subject to Availability as we consider Top competitors and their market share will be delivered.
-
8.2.13.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
-
8.2.13.2 Business Overview
-
8.2.13.3 Financials (Subject to data availability)
-
8.2.13.4 Product Types Specification
-
8.2.13.5 Business Strategy
-
8.2.13.6 S.W.O.TAnalysis
-
-
8.2.14 Dendreon Pharmaceuticals LLC (US)
Data Subject to Availability as we consider Top competitors and their market share will be delivered.
-
8.2.14.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
-
8.2.14.2 Business Overview
-
8.2.14.3 Financials (Subject to data availability)
-
8.2.14.4 Product Types Specification
-
8.2.14.5 Business Strategy
-
8.2.14.6 S.W.O.TAnalysis
-
-
8.2.15 Amgen Inc. (US)
Data Subject to Availability as we consider Top competitors and their market share will be delivered.
-
8.2.15.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
-
8.2.15.2 Business Overview
-
8.2.15.3 Financials (Subject to data availability)
-
8.2.15.4 Product Types Specification
-
8.2.15.5 Business Strategy
-
8.2.15.6 S.W.O.TAnalysis
-
-
8.2.16 AnGes
Data Subject to Availability as we consider Top competitors and their market share will be delivered.
-
8.2.16.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
-
8.2.16.2 Business Overview
-
8.2.16.3 Financials (Subject to data availability)
-
8.2.16.4 Product Types Specification
-
8.2.16.5 Business Strategy
-
8.2.16.6 S.W.O.TAnalysis
-
-
8.2.17 Inc. (Japan)
Data Subject to Availability as we consider Top competitors and their market share will be delivered.
-
8.2.17.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
-
8.2.17.2 Business Overview
-
8.2.17.3 Financials (Subject to data availability)
-
8.2.17.4 Product Types Specification
-
8.2.17.5 Business Strategy
-
8.2.17.6 S.W.O.TAnalysis
-
-
8.2.18 Enzyvant Therapeutics GmbH (Switzerland)
Data Subject to Availability as we consider Top competitors and their market share will be delivered.
-
8.2.18.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
-
8.2.18.2 Business Overview
-
8.2.18.3 Financials (Subject to data availability)
-
8.2.18.4 Product Types Specification
-
8.2.18.5 Business Strategy
-
8.2.18.6 S.W.O.TAnalysis
-
-
8.2.19 Epeius Biotechnologies Corp. (US)
Data Subject to Availability as we consider Top competitors and their market share will be delivered.
-
8.2.19.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
-
8.2.19.2 Business Overview
-
8.2.19.3 Financials (Subject to data availability)
-
8.2.19.4 Product Types Specification
-
8.2.19.5 Business Strategy
-
8.2.19.6 S.W.O.TAnalysis
-
-
8.2.20 Astellas Pharma
Data Subject to Availability as we consider Top competitors and their market share will be delivered.
-
8.2.20.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
-
8.2.20.2 Business Overview
-
8.2.20.3 Financials (Subject to data availability)
-
8.2.20.4 Product Types Specification
-
8.2.20.5 Business Strategy
-
8.2.20.6 S.W.O.TAnalysis
-
-
8.2.21 Inc. (Japan)
Data Subject to Availability as we consider Top competitors and their market share will be delivered.
-
8.2.21.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
-
8.2.21.2 Business Overview
-
8.2.21.3 Financials (Subject to data availability)
-
8.2.21.4 Product Types Specification
-
8.2.21.5 Business Strategy
-
8.2.21.6 S.W.O.TAnalysis
-
-
8.2.22 American Gene Technologies (US)
Data Subject to Availability as we consider Top competitors and their market share will be delivered.
-
8.2.22.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
-
8.2.22.2 Business Overview
-
8.2.22.3 Financials (Subject to data availability)
-
8.2.22.4 Product Types Specification
-
8.2.22.5 Business Strategy
-
8.2.22.6 S.W.O.TAnalysis
-
-
8.2.23 BioMarin (US)
Data Subject to Availability as we consider Top competitors and their market share will be delivered.
-
8.2.23.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
-
8.2.23.2 Business Overview
-
8.2.23.3 Financials (Subject to data availability)
-
8.2.23.4 Product Types Specification
-
8.2.23.5 Business Strategy
-
8.2.23.6 S.W.O.TAnalysis
-
-
Chapter 9 Qualitative Analysis (Subject to Data Availability)
-
9.1 Market Drivers
-
9.2 Market Trends
-
9.3 Market Restraints
-
9.4 Market Opportunity
-
9.5 Product Life Cycle (Subject to Data Availability)
-
9.6 Industrial Chain Analysis (Subject to Data Availability)
-
9.6.1 Industry Chain Analysis
-
9.6.2 Manufacturing Cost Analysis
-
9.6.3 Consumer Preference Analysis
-
9.6.4 Supply Side Analysis
-
9.6.4.1 Raw Material Analysis
-
9.6.4.2 Raw Material Procurement Analysis
-
9.6.4.3 Raw Material Price Trend Analysis
-
-
-
9.7 Market Attractiveness Analysis
-
9.8 PESTEL Analysis
-
9.9 Porter’s Five Forces Analysis
-
9.10 Patent Analysis (Subject to Data Availability)
-
9.11 ESG Analysis
-
9.12 Technological Road Map
Segmentation Type Analysis 2019 -2031, will provide market size split by Type. This Information is provided at Global Level, Regional Level and Top Countries Level The report with the segmentation perspective mentioned under this chapters will be delivered to you On Demand. So please let us know if you would like to receive this additional data as well. No additional cost will be applicable for the same.
Chapter 10 Market Split by Type Analysis 2019 -2031
-
10.1 Gene Silencing
-
10.1.1 Global Gene Therapy Revenue Market Size and Share by Gene Silencing 2019 -2031
-
-
10.2 Cell Replacement
-
10.2.1 Global Gene Therapy Revenue Market Size and Share by Cell Replacement 2019 -2031
-
-
10.3 Gene Augmentation
-
10.3.1 Global Gene Therapy Revenue Market Size and Share by Gene Augmentation 2019 -2031
-
-
10.4 Others
-
10.4.1 Global Gene Therapy Revenue Market Size and Share by Others 2019 -2031
-
The report with the segmentation perspective mentioned under this chapters will be delivered to you On Demand. So please let us know if you would like to receive this additional data as well. No additional cost will be applicable for the same.
Chapter 11 Market Split by Vector Analysis 2019 -2031
-
11.1 Viral Vectors
-
11.1.1 Global Gene Therapy Revenue Market Size and Share by Viral Vectors 2019 - 2031
-
-
11.2 Non-Viral Vectors
-
11.2.1 Global Gene Therapy Revenue Market Size and Share by Non-Viral Vectors 2019 - 2031
-
The report with the segmentation perspective mentioned under this chapters will be delivered to you On Demand. So please let us know if you would like to receive this additional data as well. No additional cost will be applicable for the same.
Chapter 12 Market Split by Therapeutic Area Analysis 2019 -2031
-
12.1 Neurology
-
12.1.1 Global Gene Therapy Revenue Market Size and Share by Neurology 2019 -2031
-
-
12.2 Oncology
-
12.2.1 Global Gene Therapy Revenue Market Size and Share by Oncology 2019 -2031
-
-
12.3 Hepatology
-
12.3.1 Global Gene Therapy Revenue Market Size and Share by Hepatology 2019 -2031
-
-
12.4 Others
-
12.4.1 Global Gene Therapy Revenue Market Size and Share by Others 2019 -2031
-
The report with the segmentation perspective mentioned under this chapters will be delivered to you On Demand. So please let us know if you would like to receive this additional data as well. No additional cost will be applicable for the same.
Chapter 13 Market Split by Delivery Method Analysis 2019 -2031
-
13.1 In Vivo
-
13.1.1 Global Gene Therapy Revenue Market Size and Share by In Vivo 2019 -2031
-
-
13.2 Ex Vivo
-
13.2.1 Global Gene Therapy Revenue Market Size and Share by Ex Vivo 2019 -2031
-
This chapter helps you understand the Key Takeaways and Analyst Point of View of the global Gene Therapy market
Chapter 14 Research Findings
-
14.1 Key Takeaways
-
14.2 Analyst Point of View
Here the analyst will summarize the content of entire report and will share his view point on the current industry scenario and how the market is expected to perform in the near future. The points shared by the analyst are based on his/her detailed in-depth understanding of the market during the course of this report study. You will be provided exclusive rights to interact with the concerned analyst for unlimited time pre purchase as well as post purchase of the report.
-
14.3 Assumptions and Acronyms
Sample Format of Deliverables
The Tables, Graphs/Charts are only for representative purposes and do not depict actual statistics. Purchase full Report access to actual data.
Qualitative Analysis
Research Methodology Implemented by David Fuller and Team
- 1.1 Gene Therapy Market Report 2024 Research Methodology
- 1.2 Systematic Research Approach
- 1.2.1 Primary Research for Gene Therapy Market
- 1.2.1.1 Key Data from Primary
- 1.2.1.2 Primary Interviews with Experts
- 1.2.1.3 Key Industry Insights
- 1.2.1.4 Questionnaire for Gene Therapy Market
- 1.2.1.5 Breakdown of Primaries
- 1.2.2 Secondary Research for Gene Therapy Market
- 1.2.2.1 Key Data from Secondary
- 1.2.2.2 Paid Sources
- 1.2.2.3 Public Sources
- 1.3 Market Size Estimation for Gene Therapy Market
- 1.3.1 Top-Down Approach
- 1.3.1.1 Analyzing Market Size by Top-Down Approach (Supply Side)
- 1.3.2 Bottom-UP Approach
- 1.3.2.1 Analyzing Market Size by Bottom-Up Approach (Demand Side)
- 1.3.1 Top-Down Approach
- 1.4 Market Breakdown and Data Triangulation
- 1.5 Research Assumptions for Gene Therapy Market
Key Questions Answered By Gene Therapy Market Report 2024
| Why Gene Silencing have a significant impact on Gene Therapy market? |
| What are the key factors affecting the Gene Silencing and Cell Replacement of Gene Therapy Market? |
| What is the CAGR/Growth Rate of Viral Vectors during the forecast period? |
| By type, which segment accounted for largest share of the global Gene Therapy Market? |
| Which region is expected to dominate the global Gene Therapy Market within the forecast period? |
| Segmentation Level Customization |
|
| Global level Data Customization |
|
| Region level Data Customization |
|
| Country level Data Customization |
|
| Company Level |
|
| Additional Data Analysis |
|
| Additional Qualitative Data |
|
| Additional Quantitative Data |
|
| Service Level Customization |
|
Report Format Alteration |
|
